Cornerstone Capital Management Holdings LLC. Purchases 63,701 Shares of Hologic, Inc. (HOLX)
Cornerstone Capital Management Holdings LLC. raised its position in Hologic, Inc. (NASDAQ:HOLX) by 14.8% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 494,195 shares of the medical equipment provider’s stock after buying an additional 63,701 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.18% of Hologic worth $22,425,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently made changes to their positions in HOLX. Janus Henderson Group PLC boosted its position in shares of Hologic by 556.0% in the 2nd quarter. Janus Henderson Group PLC now owns 246,752 shares of the medical equipment provider’s stock worth $11,197,000 after purchasing an additional 209,138 shares during the last quarter. Capital World Investors acquired a new stake in Hologic during the 2nd quarter worth $312,441,000. AHL Partners LLP raised its stake in Hologic by 13.1% during the 2nd quarter. AHL Partners LLP now owns 309,710 shares of the medical equipment provider’s stock worth $14,054,000 after buying an additional 35,923 shares during the period. Picton Mahoney Asset Management raised its stake in Hologic by 8.1% during the 2nd quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock worth $2,593,000 after buying an additional 4,300 shares during the period. Finally, Clinton Group Inc. acquired a new stake in Hologic during the 2nd quarter worth $410,000. Hedge funds and other institutional investors own 96.38% of the company’s stock.
Several brokerages recently commented on HOLX. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Hologic in a research note on Monday. Royal Bank Of Canada reaffirmed a “hold” rating and set a $42.00 price objective on shares of Hologic in a research note on Friday, September 22nd. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $51.00 price objective (down previously from $53.00) on shares of Hologic in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $48.38.
Hologic, Inc. (NASDAQ HOLX) traded down 0.05% during trading on Friday, reaching $37.77. The company had a trading volume of 532,321 shares. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80. The company has a market capitalization of $10.59 billion, a price-to-earnings ratio of 14.07 and a beta of 0.91. The company has a 50-day moving average price of $37.78 and a 200 day moving average price of $42.13.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million during the quarter, compared to analyst estimates of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter last year, the business posted $0.51 EPS. Analysts expect that Hologic, Inc. will post $2.01 earnings per share for the current year.
In other news, Director Elaine Ullian sold 6,902 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,745 shares of company stock valued at $768,189. Company insiders own 0.79% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.